Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Summary
The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects. The safety and tolerability of HDM1002 and rifampicin or itraconazole when given separately or together will also be evaluated.
Official title: A Phase I, Open-Label, Parallel, Fixed-Sequence Study to Evaluate the Effect of Repeated Administration of Rifampicin or Itraconazole on the Pharmacokinetics of HDM1002 in Healthy Adult Chinese Subjects
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2024-08-16
Completion Date
2024-12-30
Last Updated
2024-08-20
Healthy Volunteers
Yes
Conditions
Interventions
HDM1002 and rifampicin
Administered orally
HDM1002 and itraconazole
Administered orally
Locations (1)
The second hospital of anhui medical university
Hefei, Anhui, China